Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | NT5E | P21589 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | AHCY | P23526 | 4/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.55 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8508817 | 1.00 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL10061853 | 1.00 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL6671650 | 1.00 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL19843949 | 1.00 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL2406009 | 1.00 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL23884966 | 1.00 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL10015793 | 1.00 | ADORA3 (0.74) | ADORA3NT5ELMNAHIF1AADORA2A | |
| Phosphoric Acid SCHEMBL18490660 | 0.94 | ADORA3 (0.67) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL19843948 | 0.87 | ADORA3 (0.77) | ADORA3NT5ELMNAHIF1AADORA2A | |
| SCHEMBL4452559 | 0.87 | ADORA3 (0.77) | ADORA3NT5ELMNAHIF1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844063-A4 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2009-06-17 | — | — | EP | claimed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | claimed |
| EP-1844063-A1 | PURINE NUCLEOSIDE ANALOGS | Uti Limited Partnership (CA) | 2007-10-17 | — | — | EP | claimed |
| WO-2006081665-A1 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-10 | — | — | WO | claimed |
| US-6958318-B2 | Recombinant bacterial cells for delivery of PNP to tumor cells | THE UAB RESEARCH FOUNDATION (US) | 2005-10-25 | — | — | US | claimed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | claimed |
| US-20030228576-A1 | Nucleotide sequence coding for a cleaving enzyme; can use in conjuction with substrate to produce toxins which impair abnormal cell growth; antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-11 | — | — | US | claimed |
| EP-0715523-B1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | UAB RESEARCH FOUNDATION (US) | 2002-12-18 | — | — | EP | claimed |
| US-6491905-B1 | GENETIC VECTORS COMPRISING DNA SEQUENCE CODES FROM ESCHERICHIA PURINE NUCLEOSIDE PHOSPHORYLASE (PNP), USED AS ANTICARCINOGENS IN COMBINATION WITH PURINE ANALOGUES AS PRODRUGS; GENE THERAPY | THE UAB RESEARCH FOUNDATION | 2002-12-10 | — | — | US | claimed |
| US-6017896-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) | 2000-01-25 | — | — | US | claimed |
| EP-0715523-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1996-06-12 | — | — | EP | claimed |
| WO-1995007718-A2 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1995-03-23 | — | — | WO | claimed |
| EP-2331115-B3 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | UAB RES FOUND (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| EP-3150220-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | The UAB Research Foundation (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2331115-B1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | UAB RESEARCH FOUNDATION (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | disclosed |
| US-20030228576-A1 | Nucleotide sequence coding for a cleaving enzyme; can use in conjuction with substrate to produce toxins which impair abnormal cell growth; antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-11 | — | — | US | disclosed |
| US-6491905-B1 | GENETIC VECTORS COMPRISING DNA SEQUENCE CODES FROM ESCHERICHIA PURINE NUCLEOSIDE PHOSPHORYLASE (PNP), USED AS ANTICARCINOGENS IN COMBINATION WITH PURINE ANALOGUES AS PRODRUGS; GENE THERAPY | THE UAB RESEARCH FOUNDATION | 2002-12-10 | — | — | US | disclosed |
| US-6017896-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | ADORA3 78/4885NT5E 22/4885LMNA 1674/4885 |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | PNP, MTAP, TYMP | ADORA3 30/4885NT5E 21/4885LMNA 3355/4885 |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | PNP, UPP1, TYMP | ADORA3 974/4885NT5E 44/4885LMNA 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.